 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...205206207208209210211212213214215...235236» |
- Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients (clinicaltrials.gov) - Sep 9, 2015
P2, N=72, Completed, Sponsor: Fudan University
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Nov 2013
- alisertib (MLN8237) / Puma
Enrollment open, Combination therapy: Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors (clinicaltrials.gov) - Sep 9, 2015
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Nov 2013 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial primary completion date, Surgery, Metastases: Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer (clinicaltrials.gov) - Sep 8, 2015
P2, N=39, Recruiting, Sponsor: Fox Chase Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- Vectibix (panitumumab) / Amgen
Enrollment open: The VALENTINO study: Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) (clinicaltrials.gov) - Sep 4, 2015
P2, N=224, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- || oxaliplatin / Generic mfg., irinotecan / Generic mfg., gemcitabine / Generic mfg.
New P3 trial, Metastases: NEOPAN: A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma (clinicaltrials.gov) - Sep 3, 2015
P3, N=170, Recruiting, Sponsor: UNICANCER
- || New P2/3 trial, Metastases: Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 27, 2015
P2/3, N=134, Not yet recruiting, Sponsor: Guangxi Medical University
- ||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Metastases: AFLAME: A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy (clinicaltrials.gov) - Aug 26, 2015
P3, N=330, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial primary completion date, Metastases: NabucCO: Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 21, 2015
P1/2, N=114, Recruiting, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Dec 2015
- Rituxan (rituximab) / Roche
Trial primary completion date: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=10, Completed, Sponsor: University of California, San Francisco
Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Jun 2011 --> Dec 2005
- || New P2/3 trial: Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Aug 20, 2015
P2/3, N=432, Not yet recruiting, Sponsor: Ye Xu
- | gedatolisib (PF-05212384) / Celcuity
Trial completion, Enrollment change, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 19, 2015
P2, N=18, Completed, Sponsor: Pfizer
Trial primary completion date: Jun 2011 --> Dec 2005 Active, not recruiting --> Completed | N=190 --> 18
- || New P2/3 trial, Metastases: Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 19, 2015
P2/3, N=90, Not yet recruiting, Sponsor: Guangxi Medical University
- |||| onartuzumab (RG3638) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Aug 18, 2015
P3, N=564, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=190 --> 18 Trial primary completion date: Jul 2015 --> Oct 2015
- || napabucasin (BBI608) / Sumitomo Pharma
Enrollment change, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (clinicaltrials.gov) - Aug 17, 2015
P1, N=64, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Jul 2015 --> Oct 2015 N=32 --> 64
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (clinicaltrials.gov) - Aug 14, 2015
P1/2, N=44, Active, not recruiting, Sponsor: City of Hope Medical Center
N=32 --> 64 Trial primary completion date: Nov 2015 --> Apr 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date: Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2015
P1, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Nov 2015 --> Apr 2016 Trial primary completion date: Sep 2015 --> Sep 2016
- ||||||| NN1213 / Novo Nordisk
Trial completion, Metastases: Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2015
P3, N=570, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Completed
- Trial primary completion date, Surgery: Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed Trial primary completion date: Jul 2015 --> Jul 2020
- Trial primary completion date: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jul 2015 --> Jul 2020 Trial primary completion date: May 2015 --> May 2016
- NN1213 / Novo Nordisk
Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 13, 2015
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- Enrollment closed, Trial primary completion date, Metastases: Molecularly Tailored Therapy for Pancreas Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=20, Active, not recruiting, Sponsor: Georgetown University
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2015
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 12, 2015
P3, N=63, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2015 N=195 --> 63 | Trial primary completion date: Sep 2015 --> Dec 2014
- ||||| thioguanine / Generic mfg.
Enrollment change, Trial primary completion date: AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 12, 2015
P3, N=9022, Recruiting, Sponsor: Children's Oncology Group
N=195 --> 63 | Trial primary completion date: Sep 2015 --> Dec 2014 N=5872 --> 9022 | Trial primary completion date: Sep 2015 --> Mar 2020
- | Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 12, 2015
P3, N=380, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
N=5872 --> 9022 | Trial primary completion date: Sep 2015 --> Mar 2020 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2013 --> Sep 2014
- ||||| onartuzumab (RG3638) / Roche
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Aug 12, 2015
P3, N=564, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2013 --> Sep 2014 N=800 --> 564 | Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=734, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=800 --> 564 | Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=1000 --> 734 | Trial primary completion date: Jun 2016 --> Mar 2016
- ||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Aug 12, 2015
P3, N=183, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting | N=1000 --> 734 | Trial primary completion date: Jun 2016 --> Mar 2016 Active, not recruiting --> Completed
- |||| Inlyta (axitinib) / Pfizer
Trial completion, Metastases: A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Aug 12, 2015
P2, N=70, Completed, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| gedatolisib (PF-05212384) / Celcuity
Enrollment closed, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 11, 2015
P2, N=190, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: DEEPER: A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab (clinicaltrials.gov) - Aug 5, 2015
P2, N=360, Not yet recruiting, Sponsor: Japan Clinical Cancer Research Organization
- Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: Be TRI: A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (clinicaltrials.gov) - Aug 5, 2015
P2, N=65, Active, not recruiting, Sponsor: EPS Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> May 2017
- rosmantuzumab (OMP-131R10) / Mereo Biopharma
Enrollment open, Combination therapy, Metastases: A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 (clinicaltrials.gov) - Aug 2, 2015
P1, N=50, Recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> May 2017 Active, not recruiting --> Recruiting
- || New P3 trial: ESOPEC: Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (clinicaltrials.gov) - Jul 28, 2015
P3, N=438, Not yet recruiting, Sponsor: University Hospital Freiburg
- || New P2/3 trial: Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients (clinicaltrials.gov) - Jul 28, 2015
P2/3, N=360, Recruiting, Sponsor: Nanjing NingQi Medicine Science and Technology Co., Ltd.
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
New P2 trial: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 25, 2015
P2, N=25, Not yet recruiting, Sponsor: City of Hope Medical Center
- ||| Zydelig (idelalisib) / Gilead
Enrollment open, Combination therapy, Metastases: Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jul 24, 2015
P1, N=60, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| New P3 trial: Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection (clinicaltrials.gov) - Jul 23, 2015
P3, N=300, Recruiting, Sponsor: Fudan University
- || leucovorin calcium / Generic mfg.
New P2/3 trial: The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome (clinicaltrials.gov) - Jul 23, 2015
P2/3, N=160, Not yet recruiting, Sponsor: Rabin Medical Center
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial initiation date: Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (clinicaltrials.gov) - Jul 21, 2015
P2, N=32, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Initiation date: May 2015 --> Sep 2015
- | New P1/2 trial, Metastases: SEQUENCE: Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jul 21, 2015
P1/2, N=180, Active, not recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
- Enrollment closed: CALGB-80803: PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jul 21, 2015
P2, N=204, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Initiation date: May 2015 --> Sep 2015 Recruiting --> Active, not recruiting
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial: BALLAD: Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma (clinicaltrials.gov) - Jul 20, 2015
P3, N=100, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire Dijon
- || New P3 trial, Metastases: Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jul 17, 2015
P3, N=54, Recruiting, Sponsor: Taichung Veterans General Hospital
- || Avastin (bevacizumab) / Roche
Trial primary completion date: APPROACH: Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets (clinicaltrials.gov) - Jul 16, 2015
P2, N=218, Recruiting, Sponsor: Yonsei University
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Aug 2017
- || Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jul 16, 2015
P2, N=70, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Dec 2015 --> Apr 2015
- Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 16, 2015
P2, N=92, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Apr 2015 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Enrollment open: CAIRO5: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (clinicaltrials.gov) - Jul 16, 2015
P3, N=640, Recruiting, Sponsor: Dutch Colorectal Cancer Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Metastases: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=73, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=85, Completed, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Completed --> Active, not recruiting Recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Enrollment change, Trial primary completion date, Metastases: COMETS: Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients (clinicaltrials.gov) - Jul 15, 2015
P3, N=110, Completed, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Recruiting --> Completed Recruiting --> Completed | N=350 --> 110 | Trial primary completion date: Nov 2014 --> Apr 2015